Table 2
Open in new tab

Patient characteristics

Characteristicsn (%)
Age, median (range), yr60 (13–83)
Sex, male/female137/54 (71.7/28.3)
ECOG PS
 073 (38.2)
 1100 (52.4)
 213 (6.8)
 31 (0.5)
 Unknown4 (2.1)
Smoking status
 Never64 (33.5)
 Former or current125 (65.4)
 Unknown2 (1.0)
Histology
 Squamous cell carcinoma135 (70.7)
 Undifferentiated carcinoma27 (14.1)
 Lymphoepithelioma‐like carcinoma1 (0.5)
 Adenocarcinoma2 (1.0)
 Sarcomatoid carcinoma1 (0.5)
 Basaloid carcinoma1 (0.5)
 Papillary adenocarcinoma1 (0.5)
 Poorly differentiated neuroendocrine carcinoma18 (9.4)
 Well differentiated neuroendocrine carcinoma5 (2.6)
Staging
 Masaoka‐Koga staging
  Stage III6 (3.1)
  Stage IVa54 (28.3)
  Stage IVb95 (49.7)
  Postoperative recurrence36 (18.8)
 WHO TNM staging
  Stage III5 (2.6)
  Stage IV150 (78.5)
  Postoperative recurrence36 (18.8)
Characteristicsn (%)
Age, median (range), yr60 (13–83)
Sex, male/female137/54 (71.7/28.3)
ECOG PS
 073 (38.2)
 1100 (52.4)
 213 (6.8)
 31 (0.5)
 Unknown4 (2.1)
Smoking status
 Never64 (33.5)
 Former or current125 (65.4)
 Unknown2 (1.0)
Histology
 Squamous cell carcinoma135 (70.7)
 Undifferentiated carcinoma27 (14.1)
 Lymphoepithelioma‐like carcinoma1 (0.5)
 Adenocarcinoma2 (1.0)
 Sarcomatoid carcinoma1 (0.5)
 Basaloid carcinoma1 (0.5)
 Papillary adenocarcinoma1 (0.5)
 Poorly differentiated neuroendocrine carcinoma18 (9.4)
 Well differentiated neuroendocrine carcinoma5 (2.6)
Staging
 Masaoka‐Koga staging
  Stage III6 (3.1)
  Stage IVa54 (28.3)
  Stage IVb95 (49.7)
  Postoperative recurrence36 (18.8)
 WHO TNM staging
  Stage III5 (2.6)
  Stage IV150 (78.5)
  Postoperative recurrence36 (18.8)

Abbreviations: ECOG; Eastern Cooperative Oncology Group, PS; performance status, WHO; World Health Organization.

Table 2
Open in new tab

Patient characteristics

Characteristicsn (%)
Age, median (range), yr60 (13–83)
Sex, male/female137/54 (71.7/28.3)
ECOG PS
 073 (38.2)
 1100 (52.4)
 213 (6.8)
 31 (0.5)
 Unknown4 (2.1)
Smoking status
 Never64 (33.5)
 Former or current125 (65.4)
 Unknown2 (1.0)
Histology
 Squamous cell carcinoma135 (70.7)
 Undifferentiated carcinoma27 (14.1)
 Lymphoepithelioma‐like carcinoma1 (0.5)
 Adenocarcinoma2 (1.0)
 Sarcomatoid carcinoma1 (0.5)
 Basaloid carcinoma1 (0.5)
 Papillary adenocarcinoma1 (0.5)
 Poorly differentiated neuroendocrine carcinoma18 (9.4)
 Well differentiated neuroendocrine carcinoma5 (2.6)
Staging
 Masaoka‐Koga staging
  Stage III6 (3.1)
  Stage IVa54 (28.3)
  Stage IVb95 (49.7)
  Postoperative recurrence36 (18.8)
 WHO TNM staging
  Stage III5 (2.6)
  Stage IV150 (78.5)
  Postoperative recurrence36 (18.8)
Characteristicsn (%)
Age, median (range), yr60 (13–83)
Sex, male/female137/54 (71.7/28.3)
ECOG PS
 073 (38.2)
 1100 (52.4)
 213 (6.8)
 31 (0.5)
 Unknown4 (2.1)
Smoking status
 Never64 (33.5)
 Former or current125 (65.4)
 Unknown2 (1.0)
Histology
 Squamous cell carcinoma135 (70.7)
 Undifferentiated carcinoma27 (14.1)
 Lymphoepithelioma‐like carcinoma1 (0.5)
 Adenocarcinoma2 (1.0)
 Sarcomatoid carcinoma1 (0.5)
 Basaloid carcinoma1 (0.5)
 Papillary adenocarcinoma1 (0.5)
 Poorly differentiated neuroendocrine carcinoma18 (9.4)
 Well differentiated neuroendocrine carcinoma5 (2.6)
Staging
 Masaoka‐Koga staging
  Stage III6 (3.1)
  Stage IVa54 (28.3)
  Stage IVb95 (49.7)
  Postoperative recurrence36 (18.8)
 WHO TNM staging
  Stage III5 (2.6)
  Stage IV150 (78.5)
  Postoperative recurrence36 (18.8)

Abbreviations: ECOG; Eastern Cooperative Oncology Group, PS; performance status, WHO; World Health Organization.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close